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Recently, we created IntOGen, a resource to integrate a large amount of cancer genomic data. IntOGen aims at
facilitating the detection of the most recurrent alterations that drive tumorigenesis. It collates, annotates and analyzes
high-throughput data about transcriptional, genomic and mutational changes taking place in tumors from different
studies annotated with specific cancer types. Currently, it contains 118 studies for mRNA expression profiling and 188
studies for genomic alterations covering in total 64 different tumor topographies. In this article, we describe the
Biomart portal for IntOGen. The portal provides easy access to different types of data and facilitates the bulk download
of all the analysis results. Here, we describe the general features of IntOGen and give example queries to demonstrate
its use.
Database URL: www.intogen.org.
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Project description
Tumorigenesis is characterized by the accumulation of
a multitude of alterations. High-throughput techniques
have become common in the study of these alterations.
However, the analysis of this type of data is challenging.
One of the main difficulties is in sorting out the alter-
ations that drive tumorigenesis from those that are only
byproducts of the high number of divisions cancer cells
undergo and have no effect on the cancerogenic pheno-
type. Moreover, the existence of different types of alter-
ation makes the detection of causative ones even more
difficult. Hence, it is clear the need for approaches to ana-
lyze and integrate cancer genomics data. IntOGen inte-
grates high-throughput data related to different types
of alterations taking place in cancer such as copy
number alterations, point mutations and transcriptomic
changes from many independent studies to identify the
genes and modules (e.g. KEGG pathways, GO terms)
more significantly altered in different tumor types (1).
Data content and sources
The data in IntOGen consists of publicly available cancer
genomic studies collected from databases such as Gene
Expression Omnibus (GEO) (3), ArrayExpress (4), Cosmic
(5), Progenetix (6), the Sanger Cancer Genome Project
(http://www.sanger.ac.uk/genetics/CGP/) and the data
portal of The Cancer Genome Atlas (7). Each study contains
results from high-throughput analyses of a number of
human primary tumor samples compared to normal cells
(normal cells of the same tissue in the case of expression)
related to one or more types of cancer for a specific alter-
ation. At the first step, all the samples in the study are
annotated with appropriate terms from International
Classification of Disease for Oncology (ICD-O) (8): a topog-
raphy term indicating location in human body and, if
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fication. Studies are also annotated with the platform(s)
used for the experiment. An experiment in IntOGen consists
of a set of assays coming from the same study that have
been performed with the same platform. The analysis pipe-
line groups the assays in ‘analysis units’, which correspond
to a set of assays in one experiment annotated with the
same topography and morphology. Furthermore, ‘analysis
units’ are also created with assays in one experiment anno-
tated with the same topography and any morphology
(Figure 1). Thus, one study can generate several ‘analysis
units’. Table 1 summarizes the number of studies, experi-
ments and analysis units included in the current version of
IntOGen (v03).
Data analysis in IntOGen
In IntOGen framework, the analysis is performed at
different levels: on one side each experiment is analyzed
independently (experiment level) and those experiments
classified with the same topography and morphology
terms are combined (combination level). Also on the
other side, the analysis is performed at the level of genes
(gene level) and at the level of modules (module level).
A module is defined by a set of genes with some biological
property in common, we currently analyze Gene Ontology
(GO) modules, KEGG pathway modules, modules derived
from genes sharing a transcription factor-binding side
(TFBS) in their promoter and genes sharing microRNA
target motifs in their 30-UTR [see ref. (1) for details].
Figure 2 shows the flowchart of the analyses in IntOGen.
First, within each analysis unit, we identify genes altered in
more samples than expected by chance using Oncodrive
[see ref. (1) for details]. The results for the same gene are
combined statistically across the analyzed experiments clas-
sified with the same topography and morphology terms
using the weighted z-method (9). An advantage of ICD-O
is its hierarchical structure. If the study contains enough
samples (at least 20) for which morphology type informa-
tion is known, then detection of significant alterations can
be done at the level of topography and the level of morph-
ology. The limit of 20 samples was setup to increase the
reliability of results, as we consider that smaller number
of replicates in a large-scale study can lead to anomalous
conclusions (1). In this way, alterations specific to certain
Figure 1. Data annotation and classification. Each sample assay in a study is annotated for the platform and the ICD-O topog-
raphy and morphology terms. An experiment in IntOGen consists of a set of assays coming from the same study that have been
performed with the same platform. The analysis pipeline then generates overlapping groups of assays from the same experiment
in ‘analysis units’ in two ways, 1) according to the topography and the morphology, and 2) according to the topography (with
the morphology annotated as ‘Any morphology’).
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common to the topography of the cancer in general.
After significantly altered genes are detected, enrichment
analysis is done to find significantly altered modules (e.g.
biological processes or pathways) per experiment. In the
same way as before, the results for the same module are
combined across studies that analyze the same cancer type.
Data accessible from IntOGen Biomart
As can be expected, the interpretation of these highly
inter-related results requires powerful visualization meth-
ods. The browser of IntOGen facilitates the exploration
and intuitive visualization of results at different levels
(available at: http://www.intogen.org), while the Biomart
portal (2) (available at: http://biomart.intogen.org) allows
Figure 2. Flowchart of the analyses in IntOGen. Each analysis unit (set of assays from the same study using the same platform
and annotated with the same ICD-O terms) is analysed to detect the significantly altered genes. The gene-level experiment
results are analyzed further to detect significantly altered modules. The experiment results with the same ICD-O terms are
combined both at the gene level and at the module level. For methods details see (1).
Table 1. Summary of the data content in IntOGen (v03)
Alteration type Main data sources Number of independent
studies
Number of experiments Number of analysis units
Transcriptomic GEO 118 122 243
ArrayExpress
TCGA
Genomic (copy
number)
Progenetix 188 188 343
Sanger Cancer
Genome Project
TCGA
Total 306 310 586
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all analysis results.
In IntOGen Biomart portal, users can query for three
types of data. For each type, there is a database;
IntOGen Experiments, IntOGen Combinations and IntOGen
Oncomodules (Table 2).
In IntOGen Experiments database, there are data sets
for genomic and transcriptomic alterations. Users can
query the results of the recurrence analysis for these
alterations at the level of genes or modules, such as
KEGG pathways and GO categories, for each experiment
included in IntOGen. For both types of data sets, the results
Table 2. Databases and data sets in the BioMart of IntOGen
Databases Data sets Description
Experiments Gene genomic alterations Recurrence and significance of genomic alteration (gain and loss) for each
gene at the level of experiments
Gene transcriptomic alterations Recurrence and significance of transcriptomic alterations (upregulation and
downregulation) for each gene at the level of experiments
KEGG genomic alterations Recurrence and significance of genomic alterations (gain and loss) for each
KEGG pathway at the level of experiments
KEGG transcriptomic alterations Recurrence and significance of transcriptomic alterations (upregulation and
downregulation) for each KEGG pathway at the level of experiments
GO genomic alterations Recurrence and significance of genomic alterations (gain and loss) for each
GO term at the level of experiments
GO transcriptomic alterations Recurrence and significance of transcriptomic alterations (upregulation and
downregulation) for each GO term at the level of experiments
TFBS genomic alterations Recurrence and significance of genomic alterations (gain and loss) for
putative targets of each TF at the level of experiments
TFBS transcriptomic alterations Recurrence and significance of transcriptomic alterations (upregulation and
downregulation) for putative targets of each TF at the level of
experiments
miRNA genomic alterations Recurrence and significance of genomic alterations (gain and loss) for pu-
tative targets of each miRNA at the level of experiments
miRNA transcriptomic alterations Recurrence and significance of transcriptomic alterations (upregulation and
downregulation) for putative targets of each miRNA at the level of
experiments
Combinations Gene genomic alterations Recurrence and significance of genomic alterations (gain and loss) for each
gene at the level of combinations (tumor types and subtypes)
Gene transcriptomic alterations Recurrence and significance of transcriptomic alterations (upregulation and
downregulation) for each gene at the level of combinations (tumor types
and subtypes)
KEGG genomic alterations Recurrence and significance of genomic alterations (gain and loss) for each
KEGG pathway at the level of combinations (tumor types and subtypes)
KEGG transcriptomic alterations Recurrence and significance of transcriptomic alterations (upregulation and
downregulation) for each KEGG pathway at the level of combinations
(tumor types and subtypes)
GO genomic alterations Recurrence and significance of genomic alterations (gain and loss) for each
GO term at the level of combinations (tumor types and subtypes)
GO transcriptomic alterations Recurrence and significance of transcriptomic alterations (upregulation and
downregulation) for each GO term at the level of combinations (tumor
types and subtypes)
TFBS genomic alterations Recurrence and significance of genomic alterations (gain and loss) for pu-
tative targets of each TF at the level of combinations (tumor types and
subtypes)
TFBS transcriptomic alterations Recurrence and significance of transcriptomic alterations (upregulation and
downregulation) for putative targets of each TF at the level of combin-
ations (tumor types and subtypes)
miRNA genomic alterations Recurrence and significance of genomic alterations (gain and loss) for pu-
tative targets of each miRNA at the level of combinations (tumor types
and subtypes)
miRNA transcriptomic alterations Recurrence and significance of transcriptomic alterations (upregulation and
downregulation) for putative targets of each miRNA at the level of
combinations (tumor types and subtypes)
Oncomodules Combinations Sets of genes significantly altered in each cancer type and subtype
Experiments Sets of genes significantly altered in each experiment
.............................................................................................................................................................................................................................................................................................
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amples: genes annotated with a list of GO ids, genes in a
specific chromosomal band, a list of selected Entrez/
Ensembl gene ids. The user can also filter by significance
level and the results can be restricted to experiments done
by specific authors, performed on a specific platform type,
etc. The columns in the results can be determined by the
selections done in attributes section. For experiment-level
data, there are a number of statistics derived from the ana-
lysis that can be retrieved such as the number of samples
in the experiment, the expected/observed number of alter-
ations and P-values etc. Finally, a table that contains the
selected attributes for the genes or modules is retrieved.
In IntOGen Combinations database, users can query the
results for combinations, that is, the integration of results
from experiments annotated with the same ICD-O terms.
This database includes data sets for genomic and transcrip-
tomic alterations for genes and modules. The filters and
attributes works in a similar way as in Experiment database
but without publication nor platform attributes and filters,
and including the results attributes specific to the combin-
ation method.
In IntOGen Oncomodules database, there are two data
sets, one for combinations and one for experiments. Each
data set contains lists of genes that are significantly altered
in a specific combination of ICD-O terms or in a specific
experiment. Again the user can filter the results in a variety
of ways, with the significance level he/she likes, according
to certain characteristics of genes, for a cancer type and, in
the case of oncomodules at the level of experiments, for
author or platform type.
Query examples
Query #1 Use a list of genes to check whether they have
been significantly gained or lost in the topology breast.
Database Data sets Filters Attributes
Database:
IntOGen
Combinations
Gene
Genomic
Alterations
Genes: ID List limit
by a file with ids
(Ensembl, Entrez
etc.)
Genes>Ensembl> Gene
Ensembl ID
ICD-O topography
and morphology:
breast; ANY
morphology
Genes>Ensembl> Gene
symbol
References>External
references>Entrez
Gene id
Results>Genomics>
Gain P-value
Results>Genomics>Loss
P-value
The result of high-throughput analysis is usually a list
of genes such as genes significantly deregulated in an
expression experiment. As resources are limited, for down-
stream analysis, this gene list must be prioritized. One way
to do this is to check if the individual genes are altered in
any way in the panel of cancer experiments in IntOGen.
In Query 1, the user can download the combined results
for genomic alterations filtering them with their gene list
by clicking on the ‘ID list limit’ box and specifying the type
of id they use. For example, in order to filter using gene
symbols such TP53 and RB1, in the filters sections, the user
should check the ‘ID list limit’ box and select ‘Gene symbols’
from the drop down menu. The user can filter using a
number of ids such as GO id, Refseq, etc. In the Figure 3 a
screenshot of the web interface selecting the attributes for
this query is shown.
Query #2–3 Find the genes gained in lung cancer. Check
the transcriptomic alteration status of the genes gained in
lung cancer.
Query 2
Database Data sets Filters Attributes
IntOGen
Oncomodules
Combinations:
Oncomodules
Type of alteration:
Gain
Genes>Ensembl>
Gene Ensembl ID
ICD-O Topography
and Morphology:
lung; ANY
morphology
Query 3
Database Data sets Filters Attributes
IntOGen
Combinations
Gene
transcriptomic
alterations
Genes:
ID List from
the previous
query
Genes>Ensembl>
Gene Ensembl ID
ICD-O topography
and morphology:
lung; ANY
morphology
Genes>Ensembl>
Gene symbol
Results>
Transcriptomic>
Upregulation
P-value
Results>
Transcriptomic>
Downregulation
P-value
There are different types of alterations taking place
in cancer. It is important to cross-check the relative contri-
butions of different alteration types. With Query 2, the
user will get a list of Ensembl genes gained in ‘lung, nos;
any morphology’ experiments. The user can also retrieve
the identifier he/she chooses such as gene symbols,
EntrezGene id, etc by changing the attributes for genes.
With Query 3, the user can use the list from the previous
query, to filter the results for transcriptomic alterations.
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cancer in general and two specific morphology types;
ependymoma and astrocytoma.
Database Data sets Filters Attributes
IntOGen
Combinations
Gene genomic
alterations
ICD-O topography
and morphology:
brain; ANY
morphology
Genes>Ensembl>
Gene Ensembl ID
ICD-O topography
and morphology:
brain; astrocy-
toma, nos
Genes>Ensembl>
Gene symbol
ICD-O topography
and morphology:
brain; epedy-
moma, nos
Results>Genomics>
Gain P-value
Results>Genomics>
Loss P-value
Since the dissection of brain cancer into intrinsic subtypes
has prognostic value, it has been the interest of experi-
mental scientist to find gene list that can distinguish
cancer subtypes. With Query 4, the user can download
the genomic alterations in brain cancer and those for
specific mophologies, epedymoma and astrocytoma.
In the filters section ICD-O, multiple ICD-O terms can be
selected by clicking while keeping the control key down
for Windows machines and the command key down in
Mac machines.
Query #5 Compare the expression level of the genes
annotated with GO cell cycle term in different breast
cancer experiments. Take the results from the experiment
with the greatest number of samples.
Query 5
Database Data sets Filters Attributes
IntOGen
Experiments
Gene
transcriptomic
alterations
ICD-O topography
and morphology:
breast; ANY
morphology
Genes>Ensembl> Gene
Ensembl ID
Filters: ID List
limit by GO id:
GO:0007049
Genes>Ensembl> Gene
symbol
Results>
Transcriptomic>
Upregulation, P-value
Results>
Transcriptomic>
Downregulation, P-value
Results> Transcriptomic>
Upregulation: total
number of samples
Figure 3. Screenshot showing the attribute selection for the query 1. On the left, the selected dataset, filters and attributes are
shown. On the right the detailed attributes selection view. To retrieve the results the user should click on the ‘Results’ button on
the upper-left black bar, the ‘Count’ button gives the number of rows that match the query and the ‘New’ button allows to start
a new query.
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user can also get the results for the genes in a module.
By comparing the two results, it is possible to see which
genes from the pathway are more likely to determine the
activity of the pathway in different experiments of
the same cancer type. With Query 5, the user can filter
the results from all breast studies for the genes with cell
cycle annotation and compare the studies. To filter the re-
sults for gene with a specific GO id, in the filters section,
activate ‘ID list limit’ box and select ‘GO term ID’ as the type
of identifier.
Query #6 Compare the pathways up or downregulated
in different prostate cancer experiments.
Query 6:
Database Data sets Filters Attributes
IntOGen
Experiments
KEGG pathway
transcriptomic
alterations
ICD-O topography
and morphology:
prostate gland;
ANY morphology
KEGG
pathway id
KEGG name
Results>
Transcriptomic>
Upregulation
P-value
Results>
Transcriptomic>
Downregulation
P-value
While cancers from different patients show extensive
heterogeneity in terms of the specific genes altered, the
set of biological processes/pathway affected by these alter-
ations are similar. Enrichment analysis of sets of genes with
a specific biological property is very useful to detect such
patterns. With Query 6, the user can retrieve the results for
the pathways from KEGG for different experiments that
study breast cancer.
Query #7a Retrieve a table that lists the analysis units for
transcriptomic alterations in IntOGen.
Query 7a
Database Data sets Filters Attributes
IntOGen
Experiments
KEGG pathway
transcriptomic
alterations
None
selected
ICD-O: Topography
and morphology
EXPERIMENT: publica-
tion authors, publica-
tion year, PubMed id,
publication title,
experiment id
PLATFORM:
platform title
Query #7b Retrieve a table that lists the analysis units
for genomics alterations in IntOGen.
Query 7b
Database Data sets Filters Attributes
IntOGen
Experiments
KEGG pathway
genomic
alterations
None
selected
ICD-O: Topography and
morphology
EXPERIMENT: publica-
tion authors, publica-
tion year, PubMed id,
publication title,
experiment id
PLATFORM: platform
title
In order to retrieve the list of analysis units in IntOGen,
the user has to perform two queries, one for transcriptomic
alterations and the other for genomic alterations. This is
because the corresponding data is in different data sets.
It is important to select appropriate attributes to describe
the analysis units, use no filters and retrieve the unique
results only (click on ‘Unique results only’).
Discussion and future directions
IntOGen is a cancer analysis tool designed to facilitate the
integration, analysis, exploration and interpretation of
oncogenomic data. In addition to its browser, its BioMart
interface provides access to high-throughput data related
to genomic and transcriptomic alterations taking place in
different types of cancers. A unique feature of IntOGen is
that it provides analysis at different levels of integration.
The user can compare the results for individual experiments
to those obtained by merging the experiments studying
the same cancer type. Both types of data are accessible
through the BioMart interface. A major feature of the
BioMart interface is that it facilitates bulk download of
the data. We will continue adding new data from public
databases as well as cancer projects such as TCGA (5) and
ICGC (10).
Another advantage of using IntOGen is that the data
downloaded can directly be analyzed in Gitools (11)
(http://www.gitools.org), which is a stand-alone tool
designed for the analysis and visualization of high-
throughput data. Gitools can also be used to download
data from other available BioMart portals. For example,
one can easily perform enrichment analyses on IntOGen
data with modules or gene sets from various Biomart
portals to explore large-scale patterns in cancer genomics
data (see http://help.gitools.org/xwiki/bin/view/Tutorials/
for examples).
With cheaper and faster sequencing technologies being
available continuously, a deluge of cancer genomics data is
expected in the coming years. Resources like IntOGen that
allow the integration, visualization and interpretation of
large amount of oncogenomics data will gain importance.
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.............................................................................................................................................................................................................................................................................................We continuously work on improvements and updates on
the system to be able to incorporate the data obtained
using sequencing technologies. With more high-quality
data and new analysis methods incorporated into
IntOGen, we expect it to become an essential resource for
experimental researchers.
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